Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial
Answer : North America region will lead the global GLP-1 market during the forecast period 2026 to 2035
Purpose-built for physicians Top in women's health: GLP-1 use before pregnancy
Approximately 33% of participants withdrew from the study, with 59% of these discontinuations occurring due to reasons unrelated to treatment-emergent adverse events
doi:10.1161/CIRCULATIONAHA
Overweight and obesity management Guideline NG246
US$ 20.73
US$ 21.20
US$ 22.57
